European Journal of Cardiovascular Medicine

Background:  Prediabetes defined as blood glucose levels above the normal but below thresholds for diagnosis of diabetes, is a risk state that defines a high chance of developing diabetes. Metformin, a biguanide class of oral hypoglycaemic drug, is the first line drug for the management of type 2 DM. Pioglitazone, insulin-sensitizing Thiazolidinedione’s (TZDs), is commonly prescribed for the treatment of type 2 diabetes. TZDs are known to activate a peroxisome proliferator-activated Receptor- γ (PPAR- γ) which are ligand-activated transcription factors which belongs to the nuclear receptor superfamily. HOMA-IR is a simple and predominantly helpful laboratory tool in the evaluation of insulin resistance in prevalence studies. Material and Methods: Present study is Comparative, Prospective, randomized, Open-label, Single Center, Parallel group study conducted in Department of pharmacology at Index Medical college. Study was conducted in prediabetes patients for assessment of effects of Metformin and Pioglitazone. All patients were evaluated at baseline, 3 months for clinical and physical examination and laboratory investigation. Results: The mean difference of Fasting Blood Glucose level in Pioglitazone at baseline and after 3 months was found to be 23.8 mg/dl. The mean difference of Fasting Blood Glucose level in Metformin at baseline and after 3 months was found to be 12 mg/dl. Moreover, mean difference of Post-lunch Blood Glucose level in Pioglitazone at baseline and after 3 months was found to be 31.8 mg/dl. The mean difference of Post-lunch Blood Glucose level in Metformin at baseline and after 3 months was found to be 24 mg/dl. Conclusion: After 3 months’ treatment with Metformin and Pioglitazone, showed statically significant reduction in Blood glucose level, HOMA-IR, Serum insulin, HbA1c, Lipid Profile values. Whereas, after 3 months of treatment with Metformin and Pioglitazone caused reduction in FBG, HOMA-IR, Serum insulin, HbA1c, Lipid Profile values statistically significant decreased compare with Metformin and Pioglitazone. On the hand, Metformin reduced PPBG level, statistically highly significant compared with Pioglitazone group.